JEAN PAUL SOULILLOU professor
Course and current status
Jean-Paul SOULILLOU, MD
32Ter rue de l’Abbaye
F - 44100 NANTES
Born on 07.08.1944 à Florimont-Gaumier (24) - Married, 3 children
_________________________________________________________________
Training
- 1968: Bordeaux and Nantes medical schools, medical degree
- 1969: Interne des Hôpitaux de Nantes
- 1969: Certificat d’études spécialisées in immunology, Angers University
- 1970: Foreign cooperation in Healthcare (civil military service), Tunisia
- 1974: Research fellow, Peter Bent Brigham Hospital, Harvard Medical school
- 1975-1980: Assistant Chef de Clinique of Nantes University Hospital
- 1980: Professor of Immunology at Nantes University
Current positions
- Since 1980: Professor of Immunology at Nantes University
- Since October 2007 to 2011: Founder and Director of the “CENTAURE”, Scientific Foundation
- Emeritus Professor of Nantes University
Current academic titles / Distinctions
- Since 1998: Professor “Classe exceptionnelle”
- Since 2002: Senior Member of Institut Universitaire de France
Past or current responsibilities (selection)
- 1991-2010: Director of the Institute of Transplantation (ITERT) of Nantes University Hospital
- Founder and Director of research labs from “Institut National de la Santé et de la Recherche Médicale” (INSERM)
- Unit 643 (110 people) from 01/2004 to 12/2007, Unit 437 from 01/1995 to 12/2003, Unit 211 from 01/1986 to 12/1994.
- 1987: Coordinator of FP4 EU Biotech Network - “Immune Correlate in Rejection”
- Since 2007 : Executive board committee of EU Integrated Research Programme Xenome
- 2007-2011 director of RTRS network Centaure
- 2002-2008: Trustee of Roche Organ Transplantation Research Foundation (ROTRF)
- Member of Conseil National des Universités (National instance of nomination of Professor of Universities, 3 years)
- Member of External Advisory Boards of the NIH Immune Tolerance Network (ITN) (3 years)
- External advisory member of the Scientific Council of Paris academic hospitals (Assistance Publique) (3 years)
- Past Chairman of the Medical and Scientific Council of the French Agency of Transplantation (3 years)
- Past Member of board of directors of the Biomedicine Agency
- Member of various national scientific evaluation instances for INSERM, vice-president (CSS) (8 years)
- 2001/2011: Member of ARSEP Scientific Council, the national charitative association for research on multiple sclerosis
- Founder of Transvie/Progreffe Foundation, a charitative corporate foundation supporting transplantation science at ITERT (1994)
- Coordinator of the IHU Prometteur “European center for transplantation sciences and immunotherapy” (2011)
- Deputy Coordinator of FP7 EU grant "Translink" (2013)
Responsibility in Biotechs/Industry
- Founder of Lynatech (acquired by Sangstat corp.)
- Chairman of Scientific Council of Sangstat (1992, for 4 years)
- Co-founder of IDBC, now merged in IDBC/A2Com
- Founder of Tc Land Expression (2002) and Chairman of the International Scientific Advisory Board of Tc Land Expression (2002-2009)
- 2000: Member CIB of Fonds Bioam
- 2006/10: Member of the Scientific Council of Absorber (Sweden)
- 2005-2008: First President of Atlantic Biotherapies (a National Competitivity Cluster)
- 2008: Founder of Tc Land and EFFIMUNE (former TcL Pharma, now merged with OSE Immunopharmaceutics), President of the scientific advisory board of Effimune
- 2014 Founder of Xenothera
Editorial boards / Congress organisation
- 1st European member of Editorial Board of New England Journal of Medicine (6 years)
- Associated Editor of American Journal of Transplantation (4 years)
- Member of Editorial Boards of: Transplantation, Human Immunology, Transplant International, Xenotransplantation, Open Immunology Journal
- 1986: Chairman of 1st Basic Science Symposium of the International Transplant Society
- 1997: Chairman of the International Congress of Xenotransplantation
- 2001: Co-chairman of the International Transplant Odyssey Congress (Istanbul)
- Founder of the annual Nantes Actualités Transplantation (NAT) conference
- Chairman or Co-Chairman of 13 NAT conferences
Prizes/Member of jury
- 1989: Prize "Deneboube/Bayonne" of Ligue Nationale Française contre le Cancer
- 1998: Prize L. Binet (French Foundation for Medical Research)
- 1998: Prize Médecine/Biologie of Comité du Rayonnement Français (Sciences academy)
- 2002: Prize Eloi Collery, Academy of Medicine
- 2004: Member of the jury of “Prix du Rayonnement Français” (Sciences academy)
- 2004: Member of jury of Prize Pasteur-Weizmann/Servier
- The 2008 Transplantation Society Award for “Outstanding Achievement in Transplantation Science” (BASIC), given every two years (Sydney)
- Prix d'Honneur 2012 of INSERM (Paris)
- Medawar Prize of the TTS (Transplantation Society, 2016)
Scientific production
- Scientific publications on PubMed: > 550 (the last 5 years: 2 papers in the top 1%, 14 in the top 10%)
- Patents: 14
- Invited conferences including several plenary sessions at international conferences: 227
Visiting professorship
- Oxford, 1981 (Radcliffe Hospital)
- Circuit of invitations in Australian centres (Perth/Sydney/Melbourne)
- Houston University 2000
- Vienna University: 200
- Wellington: 2012
Scientific summary
Jean-Paul Soulillou is professor of Immunology and has been the director of several INSERM Units. He was the founder of the Institute of Transplantation at Nantes University HOSPITAL, one of Europe’s largest centres for kidney and combined kidney-pancreas transplantions and of RTRS "Centaure", a french translationnal network for Transplantation Sciences .Jean-Paul Soulillou has been a member of the international advisory committee of the "Immune Tolerance Network" (ITN) of the National Institute of Health (USA), and past president of the Medical and Scientific Council of the french transplantation agency (Etablissement Francais des Greffes, EFG). Jean-Paul Soulillou was also the first European to join the New Engl J.Medecine Editorial Board and served as Trustee of the internationnal ROTRF fundation. He was the founder and director of the RTRS “Centaure” and of the "European Center for Transplantation Sciences and Immunotherapy”. He holds the title of "Exceptional Class Professor" and is a senior member of the "Institut Universitaire de France". He has been awarded of several prizes including the Eloi Collery prize from the French Academy of Medicine, the Rayonnement Français prize and the 2008 Internationnal Award of theTransplant Society for his "outstanding contribution to transplantation science (basic science)". He founded several biotech companies (Lynatec, Tc Land, Effimune and Xenothera).
He reveived the Prix d'Honneur 2012 of INSERM, and the 2016 Medawar Prize from the Transplantation Society.
He works in immunology of transplantation and, more recently, in neuroimmunology. He was one of the first to show the role of antibody in graft rejection. He introduced new treatments on human (such as anti-Il2-R) and made important contributions in mechanisms of immune tolerance and rejection in kidney, heart and pancreas transplant and in multiple sclerosis.
He is the author of more than 550 publications (Pubmed), and have given 227 invited lectures in international meetings.
